USPTO serial 79352298
ODYSSION
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 6, 2024
- Examiner
- ALLEN, BIANCA LEIGH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ODYSSION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPPO Box 34385Washington, DC 20043-9998UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for use in medical research and scientific research being biological analysis; proteins for use in the manufacture of pharmaceuticals and reagents; proteins in raw material form for use in medical research; cells, cell lines, and cell cultures, all being cells for clinical laboratory use, for use in the production of proteins for therapeutic use | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations and substances for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; biopharmaceutical preparations and substances for treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; chemical, biochemical and biological preparations for medical and veterinary purposes for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; cells, cell lines, and cell cultures, all being cells for medical use, for use in the production of proteins for therapeutic use; reagents for medical use, namely, proteins being medical therapeutic reagents; therapeutic antibodies; vaccines | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research and design relating thereto in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; laboratory research services in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; medical and pharmacological research services; scientific research, namely, scientific analysis and testing being measurement of substances in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; scientific analysis and measurement of molecules and characteristics in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; bioanalysis services; scientific imaging services; biochemical analysis; scientific research and development services; medical research and medical development services in the field of immunology, genetic conditions, oncology, immuno-oncology, ophthalmology, haematology, neurology, respiratory diseases, metabolic conditions, infectious diseases and cardiovascular diseases; pharmaceutical research and development services; biological research and analysis; biomedical research services; biotechnological research, namely, biotechnology scientific testing, in the biotechnical, biomedical and pharmaceutical fields; chemical research and analysis; research and development of new products for others in the biotechnical, biomedical and pharmaceutical fields; pharmaceutical research and development for the pharmaceutical industry; research and development of vaccines and medicines; scientific research and development services in the field of antibodies; scientific research and development services in the field of antibody technology; scientific research and development services in the field of immunology; medical laboratory services; research of pharmaceuticals; research relating to molecular sciences; research relating to pharmaceuticals; biopharmaceutical research, development and testing being product testing services; drug discovery services; product development, namely, drug development services; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; scientific research and development of molecules for therapeutic purposes; consultancy, advisory and information services in relation to all the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by OMASS Therapeutics Limited
- Other trademarks owned by OMASS Therapeutics Limited
- Other trademarks owned by OMASS Therapeutics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ODYSSION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 2, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 10, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 10, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 6, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 6, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 6, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 21, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 21, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 21, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 1, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 1, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 1, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 16, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 16, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 16, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 16, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 16, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 7, 2023 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Sep 18, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 20, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 19, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 19, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 24, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 4, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 4, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 16, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 15, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 13, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 18, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 14, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 13, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |